

VERSION 3 JAN 09, 2024

OPEN ACCESS



DOI:

dx.doi.org/10.17504/protocol s.io.4r3l27dxxg1y/v3

Collection Citation: Katheri ne Brimblecombe, Stephanie J Cragg 2024. Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson's. . protocols.io https://dx.doi.org/10.17504/protocols.io.4r3I27dxxg1y/v3V ersion created by Cláudia C. Mendes

Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson's. V.3

Katherine

Brimblecombe^{1,2,3},

Stephanie | Cragg^{1,2,3}

¹Department of Physiology, Anatomy and Genetics, University of Oxford, OX1 3PT, UK;

²Oxford Parkinson's Disease Centre, University of Oxford, Oxford, United Kingdom;

³Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815



Cláudia C. Mendes

ABSTRACT

This collection contains five protocols detailing methods used in Brimblecombe, K.R. et al. (2023) *Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson's.*

MANUSCRIPT CITATION:

Brimblecombe KR, Connor-Robson N, Bataille CJR, Roberts BM, Gracie C, O'Connor B, Te Water Naude R, Karthik G, Russell AJ, Wade-Martins R, Cragg SJ. Inhibition of striatal dopamine release by the Ltype calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's. Eur | Neurosci. 2023 Nov 8. doi: 10.1111/ejn.16180. Epub ahead of print. PMID: 37941514.

License: This is an open access collection distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working We use this collection and it's working

Created: Jan 09, 2024

Last Modified: Jan 09, 2024

COLLECTION integer ID:

93218

Keywords: Calb1, L-type calcium channel, Parkinson's disease, dopamine D2 receptor, dopamine release, dopamine transporter, sex differences, striatum, synuclein

Funders Acknowledgement:

Aligning Science Across Parkinson's Grant ID: ASAP-020370

FILES

SEARCH

Protocol



Fast-scan cyclic voltammetry to assess dopamine release in ex vivo mouse brain

VERSION 1

CREATED BY

Cláudia C. Mendes

OPEN \rightarrow

Protocol



Making Carbon-Fibre Microelectrode (CFM) for electrochemical recordings of monoamines in ex vivo mouse brain slices

VERSION 2

CREATED BY

Cláudia C. Mendes

OPEN \rightarrow

Protocol



Synthesis of 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione OXFORD (CP8)

VERSION 2

CREATED BY

Cláudia C. Mendes

OPEN →

Protocol



Stock solutions of cocaine, isradipine, nomifensine, lidocaine, DHBE, CP8, L-741,626, and water-soluble cholesterol

VERSION 1

CREATED BY

Cláudia C. Mendes

OPEN →

Protocol



Western blot in homogenised mouse brain oxford samples

VERSION 2

CREATED BY

Cláudia C. Mendes

